255 related articles for article (PubMed ID: 24392665)
1. PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.
Huang B; Otis J; Joice M; Kotlyar A; Thomas TP
Biomacromolecules; 2014 Mar; 15(3):915-23. PubMed ID: 24392665
[TBL] [Abstract][Full Text] [Related]
2. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
[TBL] [Abstract][Full Text] [Related]
3. Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic.
Thomas TP; Huang B; Choi SK; Silpe JE; Kotlyar A; Desai AM; Zong H; Gam J; Joice M; Baker JR
Mol Pharm; 2012 Sep; 9(9):2669-2676. PubMed ID: 22827500
[TBL] [Abstract][Full Text] [Related]
4. Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel.
Saniee F; Shabani Ravari N; Goodarzi N; Amini M; Atyabi F; Saeedian Moghadam E; Dinarvand R
Pharm Dev Technol; 2021 Apr; 26(4):381-389. PubMed ID: 33538232
[TBL] [Abstract][Full Text] [Related]
5. Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA).
Mhaka A; Gady AM; Rosen DM; Lo KM; Gillies SD; Denmeade SR
Cancer Biol Ther; 2004 Jun; 3(6):551-8. PubMed ID: 15044850
[TBL] [Abstract][Full Text] [Related]
6. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
7. Folate Receptor-Targeted Dendrimer-Methotrexate Conjugate for Inflammatory Arthritis.
Qi R; Majoros I; Misra AC; Koch AE; Campbell P; Marotte H; Bergin IL; Cao Z; Goonewardena S; Morry J; Zhang S; Beer M; Makidon P; Kotlyar A; Thomas TP; Baker JR
J Biomed Nanotechnol; 2015 Aug; 11(8):1431-41. PubMed ID: 26295143
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA.
Ivanenkov YA; Machulkin AE; Garanina AS; Skvortsov DA; Uspenskaya AA; Deyneka EV; Trofimenko AV; Beloglazkina EK; Zyk NV; Koteliansky VE; Bezrukov DS; Aladinskaya AV; Vorobyeva NS; Puchinina MM; Riabykh GK; Sofronova AA; Malyshev AS; Majouga AG
Bioorg Med Chem Lett; 2019 May; 29(10):1246-1255. PubMed ID: 30904185
[TBL] [Abstract][Full Text] [Related]
9. Targeting and inhibition of cell growth by an engineered dendritic nanodevice.
Thomas TP; Majoros IJ; Kotlyar A; Kukowska-Latallo JF; Bielinska A; Myc A; Baker JR
J Med Chem; 2005 Jun; 48(11):3729-35. PubMed ID: 15916424
[TBL] [Abstract][Full Text] [Related]
10. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
[TBL] [Abstract][Full Text] [Related]
11.
Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
[TBL] [Abstract][Full Text] [Related]
12. PSMA-targeted dendrimers: a patent evaluation (WO2012078534).
Akhtar NH; Osborne JR; Fareedy SB; Tagawa ST
Expert Opin Ther Pat; 2013 May; 23(5):665-8. PubMed ID: 23581819
[TBL] [Abstract][Full Text] [Related]
13. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
Gurdag S; Khandare J; Stapels S; Matherly LH; Kannan RM
Bioconjug Chem; 2006; 17(2):275-83. PubMed ID: 16536456
[TBL] [Abstract][Full Text] [Related]
14. Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer.
Hapuarachchige S; Huang CT; Donnelly MC; Bařinka C; Lupold SE; Pomper MG; Artemov D
Mol Pharm; 2020 Jan; 17(1):98-108. PubMed ID: 31840521
[TBL] [Abstract][Full Text] [Related]
15. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer.
Lesniak WG; Boinapally S; Banerjee SR; Behnam Azad B; Foss CA; Shen C; Lisok A; Wharram B; Nimmagadda S; Pomper MG
Mol Pharm; 2019 Jun; 16(6):2590-2604. PubMed ID: 31002252
[TBL] [Abstract][Full Text] [Related]
17. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
18. MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy.
Ngen EJ; Benham Azad B; Boinapally S; Lisok A; Brummet M; Jacob D; Pomper MG; Banerjee SR
Mol Pharm; 2019 May; 16(5):2060-2068. PubMed ID: 30912947
[TBL] [Abstract][Full Text] [Related]
19. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
[TBL] [Abstract][Full Text] [Related]
20. Preparation of asymmetric urea derivatives that target prostate-specific membrane antigen for SPECT imaging.
Harada N; Kimura H; Ono M; Saji H
J Med Chem; 2013 Oct; 56(20):7890-901. PubMed ID: 24063417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
